Merck, Pfizer, Pardes Biosciences
Remember hydroxychloroquine, a malaria treatment taken by Donald Trump, and ivermectin, the horse dewormer that sent people to poison control? These drugs weren’t effective against covid-19. But people desperately wanted them to be. The dream was a pill you could swallow to make the virus go away.
Now the real thing is here: pills designed from the ground up to block the covid-19 virus. And they work. Given to people within a few days of infection, an antiviral from Pfizer slashes the chance of hospitalization by 89%. The US government has already placed orders for $10 billion worth of the new drug, called Paxlovid.
The new pill was no lucky stab in the dark. Chemists designed it to mess with the virus’s ability to copy itself. The medicine locks onto and blocks a protein, called a protease, that’s at the core of covid’s menacing replication machinery.
Similar protease enzymes exist in other types of coronavirus. That means Pfizer’s drug could also be a ready defense against the next pandemic. And scientists are sure that more pathogens like SARS-CoV-2 lurk in bat caves and industrial animal farms.
The new antiviral drugs—there’s also one from Merck that targets a different mechanism in the virus’s replication—took longer than covid vaccines to design, synthesize, and test. But they still set records. Never before has an entirely new molecule to defeat a disease gone so quickly from a chemist’s bench into the mouths of volunteers and gained approval from the US Food and Drug Administration. The CEO of Pfizer, Albert Bourla, said he was “in tears” when he got the news in November that the drug worked.
The pill will prevent many people from dying of covid-19, including people with weak immune systems for whom vaccines don’t work. And if a new variant turns up that defeats vaccines, antivirals could be our last resort.
As part of our 10 Breakthrough Technologies series, discover how covid pills were developed and what to expect next.
These scientists used CRISPR to put an alligator gene into catfish
The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.
Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.
CRISPR for high cholesterol: 10 Breakthrough Technologies 2023
New forms of the gene-editing tool could enable treatments for common diseases.
An ALS patient set a record for communicating via a brain implant: 62 words per minute
Brain interfaces could let paralyzed people speak at almost normal speeds.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.